# STANHOPE CAPITAL FORTNIGHTLY BULLETIN

### **TACTICAL POSITIONING**

We finish the year with a full weighting in equities and bonds and a positive outlook into the early months of 2025. In our first Bulletin of 2024 we wrote that a full weighting in bonds and equities was justified and that 'buying the dips' was back on the cards. This stance has been maintained across the year and has delivered positive performance aided by our preference for high relative US equity exposure and a bias for growth type companies. As we look into 2025, we may make adjustments but our long-term focus on US equities is unlikely to fade. A flexible labour force and low taxation system combined with the abundant availability of credit puts the US in a special place in the world when it comes to growth opportunities.

### **MARKET MOVES**


		Equities (incl. Dividends)								
15-Dec-24	World (\$)	US (\$)	Europe¹ (€)	UK (£)	Japan (¥)	EM (\$)	Asia (\$)			
Month to Date	0.2%	0.4%	1.2%	0.1%	3.5%	1.5%	0.7%			
Year to Date	20.9%	28.4%	10.7%	10.9%	20.1%	10.0%	12.6%			

		Commodities			Curr	Gov't		
	COM <sup>2</sup> (\$)	Gold (\$)	WTI Oil (\$)		EUR	GBP	JPY	UST 10Y <sup>3</sup>
Month to Date	0.1%	0.1%	3.7%		-0.7%	-0.9%	-2.5%	23bps
Year to Date	4.7%	28.8%	-0.5%		-4.9%	-0.9%	-8.2%	52bps

Note: Europe excluding UK; Bloomberg Commodity Index; US Treasury 10 Year Yield shows absolute, not percentage, change in yield; Source: Bloomberg

## Interest rates falling and expect more cuts in 2025

The likelihood of lower interest rates continues to support bond markets. The European Central Bank ("ECB") cut rates by 25bps from 3.25% to 3% on 12 December in order to support weak economic growth and the Swiss National Bank cut rates by 50bps on the same day to 0.5%.





In the US, the Federal Reserve ("Fed") is likely to make another four or five 25 basis point interest rate cuts in the next twelve months with the next possibly at its meeting tomorrow. In the UK, where inflation expectations have risen, in part owing to the increase in the employment tax levied on companies employing staff in the UK, the Bank of England is likely to remain cautious when it meets on Thursday and hold interest rates at current levels.

# **Political shenanigans**

For the first time in weeks political uncertainties in Europe and Asia seemed to receive more news coverage than announcements by president-elect Donald Trump. In South Korea, the Korean won weakened and the stock market initially fell on the back of President Yoon Suk Yeol's declaration of martial law and the subsequent widespread demonstrations. The decision was subsequently reversed and on 14<sup>th</sup> December, the National Assembly voted for Yoon's impeachment. The won and Korean equity market have since recovered most of their falls.

In France Michel Barnier lost a no-confidence vote in the National Assembly triggered by his austerity budget involving tax hikes and spending cuts. He was replaced by François Bayrou on 13<sup>th</sup> December and is the shortest serving French prime minister, having remained in power for three months. The European Union ("EU") expects the French government deficit to reach more than double the EU limit at 6.2% of gross domestic product ("GDP") this year.

President Bashar al-Assad of Syria fled Damascus ending his 14-year administration and the end of a 50-year family dynasty. Although Syria is not a major player in the oil industry, its location amongst significant oil producers in the Middle East and its relationship with Russia and Iran could affect the market. According to Reuters in the immediate aftermath of Assad's departure, oil prices increased by around 1% with Brent crude at \$72.14 per barrel and US West Texas Intermediate crude at \$68.37.

### **Healthcare Reckoning**

In the US fears of increased regulations in the healthcare sector and the assassination of United Health's chief executive, Brian Thompson led to weakness in the share price of many healthcare companies. Senator Elizabeth Warren and Senator Josh Hawley introduced a bipartisan bill to create pharmacy benefit manager control legislation on 11<sup>th</sup> December. If passed, the legislation would break up some of the US's biggest healthcare conglomerates. United Health's stock fell 14%, Cigna's 10% and CVS Health fell to a 12-year low last week.

# **ECONOMIC UPDATES**

Inflation has not yet reached the Fed's target of 2% and the economic outlook is still generally looking robust. Core consumer inflation, which excludes food and energy costs, rose by 0.3%, leaving the annual rate unchanged at 3.3% for the third month in a row. The November 2024 jobs report showed that nonfarm payrolls increased by 277,000 which was higher than the expected 214,000 and the Services PMI rose to its highest level in over three years at 58.5 (a number above 50 reflects growing demand). However, Manufacturing PMI fell to 48.30 points in December from 49.70 point in November. The result extends the poor momentum for US factory activity for a sixth month.

German year on year inflation rose from 2% in October to 2.2% (in September it had fallen to 1.6%). According to the Federal Statistical Office ("Destatis"), this was largely attributed to above average price increases for services.

JONATHAN BELL, IVO COULSON, NICOLE MASCARENHAS

# STANHOPE CAPITAL FORTNIGHTLY BULLETIN

### **IMPORTANT INFORMATION**

The information contained herein (the "Information") has been prepared by the Stanhope Group. The Stanhope Group comprises Stanhope Capital (Switzerland) SA and its subsidiaries, including Stanhope Capital LLP and Stanhope Capital SAS. Stanhope Capital (Suisse) SA is incorporated in Switzerland and is affiliated with SO-FIT, the Supervisory Body for Financial Intermediaries & Trustees authorised by the Swiss Financial Market Supervisory Authority (FINMA). Stanhope Capital LLP is a limited liability partnership incorporated in England and Wales authorised and regulated by the Financial Conduct Authority (FCA). Stanhope Capital LLP is regulated by the US SEC under firm number 162512. Stanhope Capital SAS is a "Société par Actions Simplifiée" incorporated in France and regulated by the Autorité de Marchés Financiers (AMF).

Acceptance of delivery of any part of this Information constitutes acceptance to the conditions of this legal disclaimer.

The Information attached is being disclosed by the member of the Stanhope Group indicated in the Information and exclusively to the intended recipient (the "Recipient").

The Information does not constitute an offer to sell or a solicitation of an offer to buy any investment fund or other financial products. The Information does not constitute investment advice or advice with respect to the suitability of any investment.

#### Restrictions

The Information is private and confidential and provided for information purposes only. No part of the Information is to be distributed, copied or disseminated directly or indirectly to anyone other than the Recipient and its professional advisers (for the sole purposes of obtaining advice). The Information should not be relied upon for tax, auditing or other purposes. The Information is not intended for any person in any jurisdiction (by way of nationality, residence, domicile or otherwise) where the publication or availability of it would be in contravention of any applicable law or regulation.

Opinions, estimates and statements contained in the Information constitute judgments of the Stanhope Group at the time of their preparation and are subject to change without notice.

The value of investments can fall as well as rise; potential income or profits are accompanied by the possibility of loss. The Recipient may not receive back the original amount invested. Past performance is not a reliable indication of future results. Performance figures included in the Information are unaudited except where indicated. Please refer to the risk warning notes provided next to any performance figures included in the Information. In certain circumstances prices stated may be historic because of the delay in obtaining prices and/or valuations from third parties. Valuations are based on either market prices available at the time of the preparation of the Information or on the Stanhope Group's reasonable estimates thereof at the time made. Valuations based upon other models or assumptions or calculated as of another date or time may result in different values. The valuation or returns on investments in currencies other than the base currency of a client's account may increase or decrease as a result of currency fluctuations.

The Stanhope Group may recommend or make investments for its clients in illiquid or volatile instruments or funds which may carry a high degree of default risk or in funds which utilise leverage/gearing which can exaggerate performance and may lead to large falls in value.

Any description of any investment process or investment management process described in the Information may change from time to time at the discretion of the Stanhope Group or otherwise.

While reasonable skill, care and diligence have been taken to ensure that the Information was accurate as at the date of writing, the Stanhope Group has not verified and accepts no legal responsibility for any third-party Information.

In addition, the Stanhope Group makes no representation, warranty, undertaking or guarantee, express or implied, as to the accuracy or empleteness of the Information and opinions therein. No members of the Stanhope Group shall be responsible for or have any liability to any

Recipient or third party for losses or damages (whether consequential, incidental or otherwise) arising (i) out of errors, omissions or changes in market factors, conditions or circumstances or (ii) from making any use of the Information.

The Information does not replace, supplement or amend the contractual documentation entered between the relevant member of the Stanhope Group and the Recipient, including but not limited to (i) the required qualifications of the Recipient in order for such Recipient to receive the Information and (ii) the disclaimers and limitation of liability contained in such contractual documentation. Further, the Information does not replace, supplement or amend the documentation applicable to any investment fund or other financial products referred to in the Information.

### **United Kingdom**

To the extent that the Information is aimed at residents of the United Kingdom, the Information has been approved for issue in the United Kingdom by Stanhope Capital LLP. Stanhope Capital LLP's advice is categorised by the Financial Conduct Authority as "restricted" because it advises on investment funds, which are only one type of "retail investment product". Stanhope Capital LLP does not provide investment advice on other retail investment products, such as life insurance, stakeholder pensions or personal pension schemes.

### **United States**

The Information is not intended for residents of the United States or for any U.S. Person. The Information is not an offer to sell any securities to or for the benefit of United States persons or the solicitation of any offer to buy securities on the part of or for the benefit of any such United States persons. For the avoidance of doubt a U.S. Person does not include a U.S. Citizen resident outside the U.S.

### France

The amount that is reasonable to invest depends on the personal circumstances of the Investor. To determine this, the Investor must consider his personal and family situation, his personal assets, his current and future needs, but also his aversion to risk. It is also strongly recommended to sufficiently diversify your investments in order to reduce the risks. Investors should inquire about this with their usual advisers (legal, tax or accounting) before any investment.

The different risk profiles can be adapted according to the allocation ranges by asset class agreed in the investment objectives defined with the client

The reports provided by Stanhope Capital regarding the management of life insurance contracts are for information purpose only, this does not replace the statement from the insurance company which remains the only formal statement to be considered for audit, tax or other purposes.